See the DrugPatentWatch profile for ozempic
Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used to improve glycemic control in adults with type 2 diabetes. According to the drug's prescribing information, Ozempic works by stimulating the release of insulin from the pancreas, suppressing glucagon secretion, and slowing gastric emptying, which in turn helps to lower daily blood sugar levels [1].
Clinical studies have shown that Ozempic can significantly reduce glycated hemoglobin (HbA1c) levels, a long-term measure of blood sugar control, as well as fasting plasma glucose levels [2]. In a 26-week trial, patients with type 2 diabetes who received Ozempic experienced a greater reduction in HbA1c levels compared to those who received a placebo [3].
It's important to note that Ozempic's effect on daily blood sugar levels can vary depending on several factors, such as the dose, the timing of administration, and the individual's response to the medication. Additionally, it's crucial to monitor blood sugar levels regularly and adjust the treatment plan as needed, under the guidance of a healthcare professional [1].
In summary, Ozempic can help lower daily blood sugar levels by stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying. Clinical studies have demonstrated its efficacy in reducing HbA1c and fasting plasma glucose levels. However, the drug's effect can vary depending on individual factors, and regular monitoring and adjustment of the treatment plan are necessary.
Sources:
[1] Novo Nordisk. (2021). Ozempic® (semaglutide) injection 0.5 mg or 1 mg. Prescribing Information.
[2] Davies, M., et al. (2018). Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in Type 2 Diabetes: A Randomised, Placebo-Controlled Trial. The Lancet, 392(10147), 475-486.
[3] Aroda, V. R., et al. (2017). Efficacy and Safety of Once-Weekly Semaglutide in Type 2 Diabetes: A Randomised, Placebo-Controlled Trial. The Lancet, 389(10086), 1399-1410.
Additional source:
DrugPatentWatch.com - For more information on Ozempic's patent landscape and related developments.